Purinergic P2X7 receptor blockade mitigates alcohol-induced steatohepatitis and intestinal injury by regulating MEK1/2-ERK1/2 signaling and egr-1 activity

Int Immunopharmacol. 2019 Jan:66:52-61. doi: 10.1016/j.intimp.2018.11.012. Epub 2018 Nov 13.

Abstract

The P2X7 receptor is an ATP-binding cation channel involved in a broad range of inflammatory diseases. However, little is known about the potential role of P2X7R in alcohol-induced steatohepatitis and intestinal injury. In our study, C57BL/6 mice were intraperitoneally injected with P2X7R antagonists Brilliant Blue G and A438079 from the 4th day to the 10th day during the induction of chronic plus binge alcohol feeding model. Our results showed that alcohol feeding induced significant steatohepatitis and liver injury, which were mitigated by P2X7R blockade as evidenced by decreased serum levels of ALT, AST, T-CHO and TG, reduced lipid accumulation, and less inflammation. The increased intestinal inflammatory cytokines production and the prominent intestinal barrier disruption caused by alcohol were also modulated by P2X7R antagonism. Interestingly, alcohol feeding increased the relative abundance of phylum Bacteroidetes while decreased the number of phylum Verrucomicrobia and genus Akkermansia in the cecal content, which were reversed by P2X7R antagonist. Importantly, the improvement of intestinal barrier function and the restoration of partial taxonomic alterations in the gut microbiota might contribute to protect the liver from gut microbiota dysbiosis-induced second hit. Furthermore, P2X7R blockade inhibited MEK1/2-ERK1/2 phosphorylation and egr-1 expression in both liver and intestine from alcohol-fed mice. Collectively, P2X7R blockade mitigates alcohol-induced steatohepatitis and intestinal injury by inhibiting MEK1/2-ERK1/2 signaling and egr-1 expression. These studies strongly suggest that P2X7R blockade may be a promising therapeutic approach for treating alcoholic liver disease.

Keywords: Early alcoholic steatohepatitis; Gut microbiota dysbiosis; Gut-liver axis; Intestinal barrier disruption; P2X7 receptor.

MeSH terms

  • Animals
  • Cytokines / metabolism
  • Disease Models, Animal
  • Early Growth Response Protein 1 / metabolism
  • Fatty Liver, Alcoholic / drug therapy*
  • Gastrointestinal Microbiome / drug effects*
  • Gastrointestinal Microbiome / physiology
  • Humans
  • Inflammation / drug therapy*
  • Intestines / drug effects*
  • Intestines / pathology
  • MAP Kinase Kinase 1 / metabolism
  • MAP Kinase Kinase 2 / metabolism
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Mitogen-Activated Protein Kinase 1 / metabolism
  • Mitogen-Activated Protein Kinase 3 / metabolism
  • Purinergic P2Y Receptor Antagonists / therapeutic use*
  • Pyridines / therapeutic use*
  • Rosaniline Dyes / therapeutic use*
  • Signal Transduction / drug effects
  • Tetrazoles / therapeutic use*

Substances

  • 3-(5-(2,3-dichlorophenyl)-1H-tetrazol-1-yl)methylpyridine
  • Cytokines
  • Early Growth Response Protein 1
  • Egr1 protein, mouse
  • Purinergic P2Y Receptor Antagonists
  • Pyridines
  • Rosaniline Dyes
  • Tetrazoles
  • Mapk1 protein, mouse
  • Mitogen-Activated Protein Kinase 1
  • Mitogen-Activated Protein Kinase 3
  • MAP Kinase Kinase 1
  • MAP Kinase Kinase 2
  • coomassie Brilliant Blue